Amicus Therapeutics
Works in Cardiovascular · Dermatology · Genetic & rare · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Women's health
Amicus Therapeutics is a clinical trial sponsor. It has 7 active clinical trials with 1,049 planned participants, across 8 therapeutic areas. Since 2021 it has completed 8 trials and stopped 2 early.
Trial track record · since 2021
Pipeline · 7 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
3 approved drug applications with a product on the market.
Questions about Amicus Therapeutics
Amicus Therapeutics is lead sponsor of 7 active clinical trials on ClinicalTrials.gov, with 1,049 planned participants, in Cardiovascular, Dermatology, Genetic & rare, Metabolic & endocrine and other areas. Since 2021 it has completed 8 trials and stopped 2 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Amicus Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-17.
Approve Suite is not affiliated with Amicus Therapeutics. Informational only.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.